Reuters
29 Sept 2025, 05:19 UTC · 51w ago
Verdict
Headline takes no side. We score MRUS +0.80 across two claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Genmab has agreed to acquire Merus NV for $8 billion in cash.
More positive than 99% of claims this week
Merus NV is developing a drug targeting head-and-neck cancer.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 63% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
The company is being acquired for $8 billion in cash, representing a significant premium and exit for shareholders.
More positive than 57% of ticker scores this week
Genmab is expanding its oncology pipeline through a strategic acquisition of Merus.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
5h ago
+30.6%
Price agrees with the score
$90.00 vs $68.89 close before publication (Sep 26) · not market-adjusted
MRUS chart →
